DS-1001b

DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity[1][2][3].

Product Specifications

CAS Number

[1898207-64-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Isocitrate Dehydrogenase (IDH)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ds-1001b.html

Purity

99.71

Solubility

DMSO : 29 mg/mL (ultrasonic)

Smiles

CC(C)(N)C.O=C(N1C2=CC=CC(/C=C/C(O)=O)=C2C(C)=C1)C3=C(C(C)(F)C)ON=C3C4=C(C=C(Cl)C=C4Cl)Cl

Molecular Formula

C29H29Cl3FN3O4

Molecular Weight

608.92

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhao Yizhaiteng, et al. Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor. WO2016052697A1.|[2]Nakagawa M, et al. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. Oncogene. 2019 Oct;38 (42) :6835-6849.|[3]Matsunaga H, et al. Characterization of a novel BBB-permeable mutant IDH1 inhibitor, DS-1001b. Annals of Oncology, 2019, 30: v145-v146.